Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P070014/S069

LifeStent 5F Vascular Stent Systems

Bard Peripheral Vascular, Inc. · Decision date Jun 10, 2026

FDA DECISIONP070014/S069

What did the FDA decide?

FDA records P070014/S069 as a supplement to PMA P070014, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 10, 2026.

FDA approval order statement

changes to the packaging supplier's adhesive coating
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 10, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P070014/S069
Regulatory pathway
PMA supplement
Product code
NIP
Decision code
OK30
Decision date
Jun 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.

Product code
NIP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P070014/S066 · Related supplement

    LifeStent Vascular Stent Systems

  2. P070014/S067 · Related supplement

    LIFESTENT FLEXSTAR & FLEXSTAR XL VASCULAR STENT SYSTEM

  3. P070014/S068 · Related supplement

    LifeStent 5F Vascular Stent System

  4. P070014/S069 received

    Application receipt date recorded by FDA.

  5. P070014/S069 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P070014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070014

Product / regulatory recordCompanyPathwayDecision dateSource
Bard Peripheral Vascular, Inc.PMA supplementDec 16, 2025FDA
Bard Peripheral Vascular, Inc.PMA supplementMar 10, 2026FDA
Bard Peripheral Vascular, Inc.PMA supplementMay 15, 2026FDA

Explore the linked device profile

Other records with product code NIP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bard Peripheral Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1415 W. 3rd St., Tempe, AZ, 85281

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records